How We WorkOrder NowSupport Privacy

Investor’s Alert – Sequenom, Inc. (NASDAQ:SQNM), Peregrine Pharmaceuticals (NASDAQ:PPHM).

on 12/03/2013

New York, NY – (Net PR News) – 3/12/2013–smartOTC is the premiere destination for Investors and novices alike who wish to receive information on fast moving OTC stocks and undiscovered companies. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

Sign up For Our No. 1 Rated Stock Newsletter to make Huge Profitshttp://www.smartotc.com

Trend analysis report of stocks at the Healthcare sector, Biotechnology industry. Sequenom, Inc. (NASDAQ:SQNM) remained a higher volume stock in its industry and Peregrine Pharmaceuticals (NASDAQ:PPHM) remained in the news during the last trading session due to their latest news and sizzling activities and both stocks showing bullish momentum during the prior trade.

Sequenom, Inc. (NASDAQ:SQNM) revealed that, in Miami, FL, the Director and EVP of Strategic Planning, Ronald M. Lindsay, Ph.D., will present at the Barclays Global Healthcare Conference, to provide a general idea and update of SQNM, at the Loews Miami Hotel, on 13th March, 2013, starting at 4:45 p.m. ET.

What Are SQNM’s Charts Signaling for Traders? Find Out Here

Healthcare sector stock, Sequenom, Inc. (NASDAQ:SQNM), during the previous trading session, showed a positive movement of +5.10%. Currently, the company has a market capitalization of $519.98 million. Stock’s closing price was $4.53 while it started its day-trade at $4.25. Its 52-week price range was $2.65 – $5.83.

SQNM traded with volume of 4.52 million shares, while its average trading remained 3.41 million shares.

If we look at the previous 5 day’s performance of the stock, it remained optimistic with the jump of 3.9%. In its last one month’s trade it declined -3.41%.

Should SQNM be a Buy or Sell Now? Find Out Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) unveiled that, in California, on Wednesday, March 20, 2013, the chief executive officer of Peregrine Pharmaceuticals, Steven W. King, will participate at the Stifel Nicolaus & Company Biotechnology Investor Day in San Francisco.

Can PPHM Show a Strong Recovery? Find out in This Research Report

Biotechnology company moving upward during the previous trading session, Peregrine Pharmaceuticals (NASDAQ:PPHM) traded with a climb of 2.53% and closed at $1.62 after gaining total volume of 4.33 million shares. Its opening price was $1.63.

Peregrine Pharmaceuticals’ earnings per share is $-0.39, while its beta value stands at 0.90 times.

If we look at the previous 5 day’s performance of the stock, it remained optimistic with the gain of 26.56%. In its last one month’s trade it decreased -23.22%. PPHM has total market capitalization of $214.71 million.

About Us:

smartOTC is the premiere destination for Investors and novice alike who wish to receive information on fast moving OTC penny stocks and undiscovered companies. We are a marketing firm that releases paid reports on undiscovered companies looking to tell their stories. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

While penny stocks pose a much more significant risk factor compared to large cap stocks, their lure of quick gains makes it a trading choice for many small time and beginner investors. There is nothing wrong with investments into penny stocks, the best advice is to do your own research and consult with your own financial professional. smartOTC reports and alerts should only be used as a starting point for your own due diligence.

Disclaimer:

PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.

Smartotc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The disclaimer is to be read and fully understood before using our site, or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Read Our Full Disclaimer at http://www.smartotc.com/disclaimer

 

Source: smartotc Posted Tue, March 12, 2013 12:37 - Permalink